| Bioactivity | Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects[1]. |
| Invitro | Bapotulimab 阻断 ILDR2 对 T 细胞活化的免疫抑制作用。Bapotulimab 具有小鼠/人交叉反应性，因为 ILDR2 在人和鼠直系同源物的细胞外结构域之间具有 98% 的序列同一性[1]。 Bapotulimab (BAY-1905254；5、25、100 或 500 ng/mL) 在体外促进 T 细胞活化并增强抗原特异性 T 细胞增殖[1]。 |
| In Vivo | Bapotulimab（BAY-1905254；10 mg/kg；腹腔注射；在第 1 天和第 4 天）显示抗原特异性 T 细胞增殖和细胞毒性显着增加[1]。 Animal Model: |
| Name | Bapotulimab |
| CAS | 2359413-58-2 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Julia Huetter, et al. Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). Cancer Immunol Res. 2020 Jul;8(7):895-911. |